A Randomized Discontinuation Phase II Trial of Deforolimus (Ridaforolimus) in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations.

Trial Profile

A Randomized Discontinuation Phase II Trial of Deforolimus (Ridaforolimus) in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2012 Planned end date changed from 1 Apr 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 03 Aug 2011 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top